Daniel L Edmonston
Overview
Explore the profile of Daniel L Edmonston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
219
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Minhas A, Bhopalwala H, Dewaswala N, Ijaz S, Khan M, Khan M, et al.
Am J Cardiol
. 2023 Jul;
202:41-49.
PMID: 37419025
Chronic kidney disease (CKD) is a major co-morbidity in patients with heart failure (HF). There are limited contemporary data characterizing the clinical profile, inhospital outcomes, and resource use in patients...
2.
Sata S, Spratt S, Edmonston D, Pagidipati N
J Hosp Med
. 2022 May;
17(5):360-363.
PMID: 35535917
No abstract available.
3.
Edmonston D, Matsouaka R, Shah S, Rajagopal S, Wolf M
Am J Cardiol
. 2021 Sep;
159:113-120.
PMID: 34497006
Volume overload promotes pulmonary hypertension (PH) through pulmonary venous hypertension. However, PH with elevated pulmonary vascular resistance (hereafter PH-PVR) may develop in patients with diseases of volume overload, such as...
4.
Herbek S, Edmonston D, Souma T
Kidney Int
. 2021 May;
99(6):1267-1269.
PMID: 34023026
While excitement has grown for the use of hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors for treating renal anemia, multiple preclinical studies have shown the complex and cell-type-dependent roles of HIFs...
5.
Cohen J, Hanff T, William P, Sweitzer N, Rosado-Santander N, Medina C, et al.
Lancet Respir Med
. 2021 Jan;
9(3):275-284.
PMID: 33422263
Background: Biological considerations suggest that renin-angiotensin system inhibitors might influence the severity of COVID-19. We aimed to evaluate whether continuing versus discontinuing renin-angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin...
6.
Edmonston D, South A, Sparks M, Cohen J
Adv Chronic Kidney Dis
. 2020 Dec;
27(5):404-411.
PMID: 33308506
Hypertension emerged from early reports as a potential risk factor for worse outcomes for persons with coronavirus disease 2019 (COVID-19). Among the putative links between hypertension and COVID-19 is a...
7.
Edmonston D, Rajagopal S, Wolf M
Kidney Int Rep
. 2020 Dec;
5(12):2275-2283.
PMID: 33305121
Introduction: Pulmonary hypertension (PH) is a common yet incompletely understood complication of chronic kidney disease (CKD). Although transthoracic echocardiogram is commonly used to noninvasively estimate PH, it has not been...
8.
Edmonston D, Isakova T, Dember L, Brunelli S, Young A, Brosch R, et al.
Am J Kidney Dis
. 2020 Dec;
77(6):920-930.e1.
PMID: 33279558
Rationale & Objective: Hyperphosphatemia is a risk factor for poor clinical outcomes in patients with kidney failure receiving maintenance dialysis. Opinion-based clinical practice guidelines recommend the use of phosphate binders...
9.
Cohen J, Hanff T, Corrales-Medina V, William P, Renna N, Rosado-Santander N, et al.
J Clin Hypertens (Greenwich)
. 2020 Sep;
22(10):1780-1788.
PMID: 32937008
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for coronavirus disease 2019 (COVID-19), is associated with high incidence of multiorgan dysfunction and death. Angiotensin-converting enzyme 2 (ACE2), which...
10.
Edmonston D, Roe M, Block G, Conway P, Dember L, DiBattiste P, et al.
Am J Kidney Dis
. 2020 Aug;
76(6):842-850.
PMID: 32768631
Occasional bursts of discovery and innovation have appeared during the otherwise stagnant past several decades of drug development in nephrology. Among other recent drug discoveries, the unexpected kidney benefits observed...